Document is current
Any future updates will be listed below
-
Authors
Yu, James B.
Folkert, Michael R.
Sato, Ryoko
Collins, Sean
Hankins, Ryan
Mehta, Parthiv
Bhattacharyya, Samir
Ezekekwu, Emmanuel
Hamstra, Daniel A.
-
Funding
Funding for this research was provided by:
Boston Scientific Corporation
- License Information
-
More Information
Article History
Received: 11 April 2025
Accepted: 30 June 2025
First Online: 7 July 2025
Declarations
:
: Ryoko Sato, Samir Bhattacharyya, and Emmanuel Ezekekwu are employees of Boston Scientific. James Yu reports consulting fees from Boston Scientific, Teleflex, and AlphaSights, research support from Pfizer/Myovant/Sumitomo Pharma, and is a stockholder of Modifi Bio. Michael Folkert has received travel reimbursement from Varian and Boston Scientific, and his affiliated institutions have received funding for clinical trials from Boston Scientific. Ryan Hankins is a clinical consultant for Boston Scientific. Sean Collins is a consultant for Boston Scientific. Daniel Hamstra is a paid consultant for Boston Scientific.
: The study was exempt from Institutional Review Board (IRB) approval as this research project used data from an anonymous, de-identified, medical clearinghouse administrative claims database compliant with the Health Insurance Portability and Accountability Act of 1996.
